NO942708L - Parathyroid hormon og raloxifen for å öke benmassen - Google Patents

Parathyroid hormon og raloxifen for å öke benmassen

Info

Publication number
NO942708L
NO942708L NO942708A NO942708A NO942708L NO 942708 L NO942708 L NO 942708L NO 942708 A NO942708 A NO 942708A NO 942708 A NO942708 A NO 942708A NO 942708 L NO942708 L NO 942708L
Authority
NO
Norway
Prior art keywords
raloxifene
bone mass
parathyroid hormone
increase bone
pth
Prior art date
Application number
NO942708A
Other languages
English (en)
Norwegian (no)
Other versions
NO942708D0 (no
Inventor
Janet Mary Hock
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO942708D0 publication Critical patent/NO942708D0/no
Publication of NO942708L publication Critical patent/NO942708L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO942708A 1993-07-22 1994-07-19 Parathyroid hormon og raloxifen for å öke benmassen NO942708L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9648093A 1993-07-22 1993-07-22

Publications (2)

Publication Number Publication Date
NO942708D0 NO942708D0 (no) 1994-07-19
NO942708L true NO942708L (no) 1995-01-23

Family

ID=22257534

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942708A NO942708L (no) 1993-07-22 1994-07-19 Parathyroid hormon og raloxifen for å öke benmassen

Country Status (29)

Country Link
US (1) US5510370A (enExample)
EP (1) EP0635270B1 (enExample)
JP (1) JPH0769920A (enExample)
KR (1) KR100306852B1 (enExample)
CN (1) CN1105577C (enExample)
AT (1) ATE189959T1 (enExample)
AU (1) AU686628B2 (enExample)
BR (1) BR9402902A (enExample)
CA (1) CA2128376A1 (enExample)
CY (1) CY2192B1 (enExample)
CZ (1) CZ289648B6 (enExample)
DE (1) DE69423146T2 (enExample)
DK (1) DK0635270T3 (enExample)
ES (1) ES2142380T3 (enExample)
GR (1) GR3033492T3 (enExample)
HU (1) HU219382B (enExample)
IL (1) IL110350A (enExample)
MY (1) MY124311A (enExample)
NO (1) NO942708L (enExample)
NZ (2) NZ264027A (enExample)
PE (1) PE14595A1 (enExample)
PH (1) PH30686A (enExample)
PL (1) PL304348A1 (enExample)
PT (1) PT635270E (enExample)
RU (1) RU2155042C2 (enExample)
SI (1) SI0635270T1 (enExample)
TW (1) TW303299B (enExample)
YU (1) YU49170B (enExample)
ZA (1) ZA945249B (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1996040098A2 (en) 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US6319914B1 (en) 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5578613A (en) * 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5811120A (en) * 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5972383A (en) * 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5502074A (en) * 1994-08-22 1996-03-26 Eli Lilly And Company Benzothiophenes for bone healing and fracture repair
WO1996007416A1 (en) * 1994-09-09 1996-03-14 The Procter & Gamble Company Estrogens and parathyroid hormone for treating osteoporosis
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
CN1173819A (zh) * 1995-02-06 1998-02-18 伊莱利利公司 抑制il－6作用的方法
JP3263598B2 (ja) * 1995-11-01 2002-03-04 有限会社ドット 経鼻吸収用生理活性ペプチド組成物
AU761274B2 (en) * 1996-01-29 2003-05-29 Schering Aktiengesellschaft Pharmaceutical combination preparation that consists of LHRH-analogues and antiestrogens for treating gynecological disorders
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
EP1016412A4 (en) * 1997-07-22 2001-05-02 Chugai Pharmaceutical Co Ltd DENTISTRY WITH PTH
CA2306344A1 (en) * 1997-10-14 1999-04-22 Masahiko Sato Method of building and maintaining bone
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
CA2346695A1 (en) * 1998-10-07 2000-04-13 The Board Of Trustees Of The University Of Arkansas Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof
WO2000028982A2 (en) 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
US20040214889A1 (en) * 1999-07-31 2004-10-28 Smithkline Beecham Corporation Calcilytic compounds
WO2001022093A1 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
EP1339312B1 (en) * 2000-10-10 2006-01-04 Microchips, Inc. Microchip reservoir devices using wireless transmission of power and data
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
MXPA04005112A (es) * 2001-11-29 2005-04-29 Gtx Inc Prevencion y tratamiento de osteoporosis inducida por privacion de androgeno.
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US7247609B2 (en) * 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
RU2355397C2 (ru) * 2002-06-13 2009-05-20 Уайт Режимы лечения базедоксифеном
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
WO2004022033A1 (en) * 2002-09-04 2004-03-18 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
SG149081A1 (en) * 2004-01-13 2009-01-29 Wyeth Corp Treatment of aromatase inhibitor therapy-related osteoporosis
MXPA06013168A (es) 2004-05-13 2007-05-15 Johnson & Johnson Aparato y metodo para el suministro transdermico de agentes de la hormona paratiroidea.
US7648965B2 (en) * 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7531518B2 (en) * 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
US20080076975A1 (en) * 2005-01-25 2008-03-27 Microchips, Inc. Method and implantable device with reservoir array for pre-clinical in vivo testing
AU2006208131A1 (en) * 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
US7691105B2 (en) * 2005-09-26 2010-04-06 Depuy Spine, Inc. Tissue augmentation, stabilization and regeneration technique
US20070088436A1 (en) * 2005-09-29 2007-04-19 Matthew Parsons Methods and devices for stenting or tamping a fractured vertebral body
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
WO2007059470A2 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20070168041A1 (en) * 2006-01-17 2007-07-19 Sudhakar Kadiyala Method and instruments for intervertebral disc augmentation through a pedicular approach
SI3345607T1 (sl) 2006-12-29 2023-03-31 Ossifi-Mab Llc Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE
WO2008125655A1 (en) * 2007-04-13 2008-10-23 Kuros Biosurgery Ag Polymeric tissue sealant
US8241363B2 (en) 2007-12-19 2012-08-14 Depuy Spine, Inc. Expandable corpectomy spinal fusion cage
US8241294B2 (en) * 2007-12-19 2012-08-14 Depuy Spine, Inc. Instruments for expandable corpectomy spinal fusion cage
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
US8876905B2 (en) * 2009-04-29 2014-11-04 DePuy Synthes Products, LLC Minimally invasive corpectomy cage and instrument
WO2011071480A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
EP2558106A1 (en) * 2010-04-16 2013-02-20 Novartis AG Methods and compositions for improving implant osseointegration
ES2882852T3 (es) 2011-03-16 2021-12-02 Kuros Biosurgery Ag Formulación farmacéutica para la utilización en la fusión espinal
JP6683628B2 (ja) * 2014-06-04 2020-04-22 シーダーズ−サイナイ メディカル センター 脊椎圧迫骨折の非外科的修復のための方法
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE4039656A1 (de) * 1990-12-12 1992-06-17 Bissendorf Peptide Gmbh Arzneimittel, enthaltend das humane parathormon-fragment (1-37) in der form des amids oder ethylamids als aktiven wirkstoff
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

Also Published As

Publication number Publication date
NZ264027A (en) 1996-03-26
DK0635270T3 (da) 2000-06-05
GR3033492T3 (en) 2000-09-29
IL110350A (en) 2002-02-10
EP0635270A1 (en) 1995-01-25
EP0635270B1 (en) 2000-03-01
HK1013800A1 (en) 1999-09-10
ZA945249B (en) 1996-01-18
DE69423146T2 (de) 2000-09-21
KR950002785A (ko) 1995-02-16
RU2155042C2 (ru) 2000-08-27
CN1105577C (zh) 2003-04-16
PH30686A (en) 1997-09-16
CY2192B1 (en) 2002-11-08
ES2142380T3 (es) 2000-04-16
CN1105882A (zh) 1995-08-02
ATE189959T1 (de) 2000-03-15
DE69423146D1 (de) 2000-04-06
AU6757794A (en) 1995-02-02
YU46794A (sh) 1997-03-07
RU94027680A (ru) 1996-11-10
HU9402157D0 (en) 1994-09-28
CA2128376A1 (en) 1995-01-23
IL110350A0 (en) 1994-10-21
AU686628B2 (en) 1998-02-12
BR9402902A (pt) 1995-04-11
PE14595A1 (es) 1995-06-01
PT635270E (pt) 2000-07-31
CZ173394A3 (en) 1995-04-12
MY124311A (en) 2006-06-30
PL304348A1 (en) 1995-01-23
SI0635270T1 (en) 2000-08-31
KR100306852B1 (ko) 2001-11-30
US5510370A (en) 1996-04-23
HUT67945A (en) 1995-05-29
YU49170B (sh) 2004-05-12
HU219382B (en) 2001-03-28
NZ280040A (en) 1997-06-24
NO942708D0 (no) 1994-07-19
TW303299B (enExample) 1997-04-21
JPH0769920A (ja) 1995-03-14
CZ289648B6 (cs) 2002-03-13

Similar Documents

Publication Publication Date Title
NO942708D0 (no) Parathyroid hormon og raloxifen for å öke benmassen
GB2033885B (en) Method for treating waste anaesthetic gas
NO942241D0 (no) Fremgangsmåte for behandling av osteoporose ved behandling av bisfosfonater og parathyreoideahormon
ATE190496T1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
BG46024A1 (en) Method and device for treatment of bone patology
GB2110932A (en) Method and composition for treating acne
PH21102A (en) Improvements in or relating to benzothiophene derivatives as antiastmatic agents
EP0238553A4 (en) TREATMENT OF A CATABOLIC DEREGULATION.
HUT47427A (en) Bezafibrat for treating diabetes
EP0515434A4 (en) Method for treating intestinal diseases
JPS54101799A (en) Method of treating natural calcite
DK0579488T3 (da) Præparat til behandling af mastitis og matritis
DE2962479D1 (en) Method and apparatus for treating bovine feet
IT1188163B (it) Trattamento dell'osteoporosi
JPS54120969A (en) Cremation treatment method and its device
JPS54114473A (en) Treatment method and apparatus for stabilizing waste sodium
GB2132505B (en) Treatment of town's refuse
GB2043458B (en) Orthopaedic fracture fixation apparatus
BG27406A1 (en) Operative method for medical treating of luxsation fibolous tendons
RU1769866C (en) Method for treatment of tendons and sites of their attachment to bone of upper arm
DK148289D0 (da) Fremgangsmaade og apparat til elektrolytisk vandbehandling
JPS5556200A (en) Natural leather treating agent and method
IT8048453A0 (it) Trattamento dell'iperacidita' ga composizione farmaceutica per ilstrica gastriti e ulcere gastroduo denali
SU1572581A1 (ru) Cпocoб лeчehия диaфизaphыx пepeлomob kocteй пpeдплeчья
PL246604A1 (en) Rehabilitation gymnastics appliance for treating upper limb hemiparesis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application